Nanollose
Market Cap
AU$3.4m
Last Updated
2020/05/29 11:02 UTC
Data Sources
Company Financials
Executive Summary
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia.
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Nanollose's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NC6's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.3%
NC6
-3.3%
AU Biotechs
5.1%
AU Market
1 Year Return
-43.3%
NC6
41.0%
AU Biotechs
-9.4%
AU Market
Return vs Industry: NC6 underperformed the Australian Biotechs industry which returned 41% over the past year.
Return vs Market: NC6 underperformed the Australian Market which returned -9.4% over the past year.
Shareholder returns
| NC6 | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.3% | -3.3% | 5.1% |
| 30 Day | 30.8% | -9.3% | 11.1% |
| 90 Day | -26.1% | -6.3% | -9.3% |
| 1 Year | -37.4%-43.3% | 42.4%41.0% | -5.7%-9.4% |
| 3 Year | n/a | 124.5%116.9% | 14.4%-0.8% |
| 5 Year | n/a | 219.7%199.8% | 30.9%2.7% |
Price Volatility Vs. Market
How volatile is Nanollose's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Do Institutions Own Nanollose Limited (ASX:NC6) Shares?2 months ago | Simply Wall St
Investors Who Bought Nanollose (ASX:NC6) Shares A Year Ago Are Now Down 47%3 months ago | Simply Wall St
Nanollose (ASX:NC6) Will Have To Spend Its Cash WiselyValuation
Is Nanollose undervalued compared to its fair value and its price relative to the market?
4.26x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NC6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NC6 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NC6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NC6 is overvalued based on its PB Ratio (4.3x) compared to the AU Biotechs industry average (2.7x).
Next Steps
Future Growth
How is Nanollose forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
15.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanollose has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Nanollose's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Nanollose competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Nanollose performed over the past 5 years?
-36.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NC6 is currently unprofitable.
Growing Profit Margin: NC6 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NC6 is unprofitable, and losses have increased over the past 5 years at a rate of -36.9% per year.
Accelerating Growth: Unable to compare NC6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NC6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: NC6 has a negative Return on Equity (-260.8%), as it is currently unprofitable.
Next Steps
Financial Health
How is Nanollose's financial position?
Financial Position Analysis
Short Term Liabilities: NC6's short term assets (A$624.3K) exceed its short term liabilities (A$120.2K).
Long Term Liabilities: NC6's short term assets (A$624.3K) exceed its long term liabilities (A$24.7K).
Debt to Equity History and Analysis
Debt Level: NC6 is debt free.
Reducing Debt: NC6 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NC6 has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NC6 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.
Next Steps
Dividend
What is Nanollose's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NC6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NC6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NC6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NC6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NC6's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average board tenure
CEO
Alfie Germano
no data
Tenure
AU$299,889
Compensation
Mr. Raffaele Germano, also known as Alfie, has been Managing Director of Nanollose Limited since August 9, 2017 and also serves as its Chief Executive Officer. Mr. Germano is responsible for the operations ...
CEO Compensation Analysis
Compensation vs Market: Alfie's total compensation ($USD199.65K) is about average for companies of similar size in the Australian market ($USD254.05K).
Compensation vs Earnings: Alfie's compensation has been consistent with company performance over the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | AU$264.05k | 7.83% A$265.1k | |
| CEO, MD & Director | no data | AU$299.89k | 0.66% A$22.4k | |
| Non-Executive Director | no data | AU$35.00k | 7.4% A$250.6k | |
| Non-Executive Director | 3.75yrs | AU$35.01k | 0.66% A$22.4k | |
| Independent Non-Executive Director | 0.83yr | no data | no data |
2.8yrs
Average Tenure
Experienced Board: NC6's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NC6 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41%.
Top Shareholders
Company Information
Nanollose Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nanollose Limited
- Ticker: NC6
- Exchange: ASX
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$3.384m
- Shares outstanding: 105.75m
- Website: https://www.nanollose.com
Location
- Nanollose Limited
- CPC
- Suite 5
- Nedlands
- Western Australia
- 6009
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NC6 | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Oct 2017 |
| NC6 | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Oct 2017 |
Biography
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre; and a commercial supply chain of microbial cellulose from various waste streams. The company’s products are used in textile, nonwoven fabric, and other industries. The company was founded in 2014 and is based in Nedlands, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/29 11:02 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.